Stempoint Capital LP Purchases New Shares in Sensei Biotherapeutics, Inc. $FTH

Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 132,873 shares of the company’s stock, valued at approximately $4,188,000. Stempoint Capital LP owned approximately 9.92% of Sensei Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

Separately, Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $28.93 on Thursday. The stock has a market cap of $38.77 million, a price-to-earnings ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 12-month low of $6.87 and a 12-month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. On average, analysts predict that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 49,494 shares of company stock worth $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on FTH shares. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Leerink Partners began coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target for the company. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Finally, Robert W. Baird started coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.75.

Sensei Biotherapeutics Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.